NCT05417971 2026-04-16
Reduced Intensity Fludarabine and TBI Prior to Haplo-Identical Transplantation
Northside Hospital, Inc.
Recruiting
Clinical Trials
8 trialsNCT04959175 2026-04-09
Phase I/II Study to Reduce Post-transplantation Cyclophosphamide Dosing for Older or Unfit Patients Undergoing Bone Marrow Transplantation for Hematologic Malignancies
National Institutes of Health Clinical Center (CC)
Phase 1/2 Recruiting
NCT05436418 2026-03-20
The Lowest Effective Dose of Post-Transplantation Cyclophosphamide in Combination With Sirolimus and Mycophenolate Mofetil as Graft-Versus-Host Disease Prophylaxis After Reduced Intensity Conditioning and Peripheral Blood Stem Cell Transplantation
National Institutes of Health Clinical Center (CC)
Phase 1/2 Recruiting
NCT06028828 2026-02-02
ADAPT
University of California, Irvine
Phase 2 Recruiting
NCT06252870 2026-01-26
CY-MET-RIC
Nantes University Hospital
Phase 2 Recruiting
NCT07162038 2026-01-23
Phase I Trial Integrating HLA-Haploidentical Anti-CD19 CAR-T Cells With Post-Transplantation Cyclophosphamide-Based HLA-Haploidentical Hematopoietic Cell Transplantation
National Institutes of Health Clinical Center (CC)
Phase 1 Recruiting
NCT03670966 2025-10-16
211At-BC8-B10 Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory High-Risk Acute Leukemia or Myelodysplastic Syndrome
Fred Hutchinson Cancer Center
Phase 1/2 Recruiting
NCT06125483 2025-04-24
TBI/Flu/Bu/Mel Combined With Secondary UCBT in Patients With Hematological Malignancies Who Relapsed After Allo-HSCT
The First Affiliated Hospital of Soochow University
Phase NA Recruiting